Samir D. Undevia

Genetic Variants in the <i>UDP-glucuronosyltransferase 1A1</i> Gene Predict the Risk of Severe Neutropenia of Irinotecan

Federico Innocenti, Samir D. Undevia, Lalitha Iyer et al. · Journal of Clinical Oncology · 2004 · 954 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Robert G. Maki, David R. D’Adamo, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2009 · 573 citations · Full text

Medicine, Oncology, Cancer Pharmacology +15

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Gary K. Schwartz, William D. Tap, Li-Xuan Qin et al. · The Lancet Oncology · 2013 · 187 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

Michael L. Maitland, Kristen Kasza, Theodore Karrison et al. · Clinical Cancer Research · 2009 · 175 citations · Full text

Medicine, Oncology, Pharmacology +16

Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the <i>UGT1A1</i> Genotype of Patients With Cancer

Federico Innocenti, Richard L. Schilsky, Jacqueline Ramı́rez et al. · Journal of Clinical Oncology · 2014 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17